Physician profile
Scott C Feitell
NPI 1770815540
$422,340.06
in general payments reported to CMS, 2019-2025
38 companies · $53K in 2025
The $53K reported for 2025 was more than what 93% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $54K · 2021: $68K · 2022: $38K · 2023: $76K · 2024: $76K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Honoraria: $42K · Travel and Lodging: $15K · Consulting Fee: $15K · Food and Beverage: $11K · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,039.00 |
| Honoraria | $41,530.00 |
| Travel and Lodging | $15,016.41 |
| Consulting Fee | $14,949.50 |
| Food and Beverage | $10,724.59 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $67,727.71 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Pfizer INC. | $60,209.28 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $47,204.73 | 2019-2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $40,999.29 | 2021-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $40,186.97 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $33,464.61 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals Lp | $32,972.71 | 2020-2025 | Farxiga, Wainua |
| Scpharmaceuticals INC. | $31,387.70 | 2023-2025 | |
| Vifor Pharma, INC. | $21,128.36 | 2019-2021 | |
| Bridgebio Pharma, INC. | $15,064.61 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $10,436.28 | 2021-2025 | Optimizer, Optimizer |
| Akcea Therapeutics, INC. | $5,571.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $5,025.60 | 2020-2024 | Xarelto |
| Sensible Medical Innovations INC | $3,727.97 | 2019 | |
| Medicure Pharma INC. | $3,000.00 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,447.56 | 2021-2025 | |
| Cvrx, INC. | $561.27 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $434.51 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Abiomed | $310.74 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.06 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $209.88 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $167.01 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Getinge USA Sales, LLC | $119.36 | 2019 | |
| Kestra Medical Technology Services, INC. | $111.89 | 2022-2025 | Assure Wcd |
| Amgen INC. | $81.29 | 2019-2023 | Repatha |
| Atricure, INC. | $77.95 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.45 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $73.21 | 2023-2025 | Camzyos |
| United Therapeutics Corporation | $66.29 | 2020-2025 | Tyvaso, Tyvaso, Orenitram |
| Liquidia Technologies, INC. | $59.50 | 2025 | Yutrepia |
| Kiniksa Pharmaceuticals, Ltd. | $34.05 | 2022-2023 | Arcalyst |
| Boston Scientific Corporation | $30.35 | 2024 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $25.14 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $24.05 | 2025 | Injectafer |
| Glaxosmithkline, LLC. | $21.00 | 2023 | Arexvy, Shingrix |
| Medtronic Vascular, INC. | $19.78 | 2020 | |
| Livanova USA, INC. | $17.99 | 2021 | |
| Esperion Therapeutics, INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Feitell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.